Specifically, we propose that the CXCR5/CXCL13-axis may represent an additional target for anti-PD-1 therapy in cutaneous melanoma, that is relevant for treatment outcome as well as a potential source of predictive therapeutic biomarkers (summarized in Figure 2). The gene discussed is CXCL13; the disease is cutaneous melanoma.